Preparation and Preclinical Study of 99mTc-labeled Prostate Cancer Aptamer
- VernacularTitle:99m锝标记前列腺癌PSMA适配体的制备和临床前研究
- Author:
Ting YANG
1
;
Ju JIAO
;
ting Yin LÜ
;
Qiong ZOU
;
e Su CAO
;
qin Shu JIANG
;
Yong ZHANG
Author Information
1. 中山大学附属第三医院核医学科
- Keywords:
prostate cancer;
PSMA;
aptamer;
99mTc;
SPECT/CT imaging
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2017;38(6):848-853
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To radiolabel the PSMA aptamer A10-3.2 with 99mTc , and explore its biological characteristics in vivo and in vitro.[Methods]Using Succinimidyl 6-hydrazinonicotinate hydrochloride (SHNH) as the bifunctional chelating agent to label aptamer A10-3.2 with 99mTc, then tested for the stability in vitro, the specific uptake by prostate cancer LNCaP cells (PSMA+) , the characteristics of SPECT/CT imaging and biodistribution in LNCaP tumor-bearing NOD/SCID mice.[Results]The labeling rate and radiochemical purity of the products (99mTc-SHNH-A10-3.2) are(71.31 ± 6.78)% and 97.03%,respectively. 99mTc-SHNH-A10-3.2 had obvious target specificity for PSMA positive prostate cancer LNCaP cells, its uptake rate was significantly higher than PSMA nega?tive PC-3 cells (P<0.01). And in tumor-bearing mice, the tumor has a certain uptake and a high ratio of the tumor tissue to the mus?cle.[Conclusion]This study successfully constructed 99mTc-labeled PSMA-targeted aptamer A10-3.2, which has a good stability and targeting in vivo and in vitro, has a high tumor tissue/muscle ratio in tumor-bearing mice, which show that it may be a potential target?ed molecular imaging agent for prostate cancer.
